biotech

Bio-Analyst

Research Platform
person
arrow_backExplore/Bacopa
Tier-APublic-ready7/6/2026

Bacopa

Cognition, memory, and focus is the main area connected here, and any felt benefit should be read together with the human evidence base.

Some human supplement-context evidence is present and directly informs the score.

Representative tier calculated from paper evidence that passed the collection audit.

Papers analyzed
72
Caution signal
Low
Representative score
81.5
Cognition, memory, and focusStress Response and Sleep ChangesExercise performance and recovery

Main benefit evidence

The representative ingredient tier is calculated from these target-level evidence groups.

Cognition and focus
13 studiesTier-S
Cognition, memory, and focus
Fairly consistent positive signal in studiesFelt benefit focusSupplement context

Potential benefit studied in Cognition and focus.

Evidence score
85.0
Study context
Supplement context

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Stress and mood
3 studiesTier-B
Stress Response and Sleep Changes
Fairly consistent positive signal in studiesFelt benefit focusSupplement context

These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.

Evidence score
55.6
Study context
Supplement context

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Exercise performance and recovery
1 studiesTier-C
Exercise performance and recovery
Some positive signal observedFelt benefit focusSupplement context

Potential benefit studied in Exercise performance and recovery.

Evidence score
20.9
Study context
Supplement context

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Recent research

Updated This Month10 new papers

Observed range in repeated studies

This range includes studies in specific patient groups. It is not a general dose or recommendation.

Lower observed study value
160
mg/day
Higher observed study value
599
mg/day
Only ranges repeated in human, oral, single-ingredient studies are shown.
Not personal dosing instructions, recommendations, or safety limits.

Side effects and combination findings in studies

Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.

Caution index
0.6
Caution band: Low
Caution signals
3
Side effects + combos + curated rules
Key precautions
No curated contraindication rule is available yet, but literature caution signals are shown below.
These are signals reported in studies. They do not predict what will happen to an individual.

Findings to review with care

Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.

Side effects reported when this ingredient was used alone

Symptoms or adverse events reported in studies of this ingredient without another active ingredient.

mild side-effects1 papers
Only 2.3% of participants reported mild side-effects, indicating good tolerability.Human studies · Systematic review
Gastrointestinal tract side-effects1 papers
Bacopa monnieri administration was associated with gastrointestinal side effects including increased stool frequency, abdominal cramps, and nausea.Human studies · Randomized controlled trial
Adverse events (stomach upset)1 papers
Bacopa monnieri was well tolerated with few adverse events, primarily mild stomach upset, occurring in 9 participants compared to 10 in the placebo group.Human studies · Randomized controlled trial

Evidence summaries

Paper IDs and full lists are private. Only study types and summaries are shown.

Key Evidence #1
Public scholarly dataCitation signal: 306
rct

[Abstract]: A study is reported on the effects of Brahmi (Bacopa monniera) on human memory. Seventy-six adults aged between 40 and 65 years took part in a double-blind randomized, placebo control study in which various memory functions were tested and levels o

Key Evidence #2
Public scholarly dataCitation signal: 277
rct

[Abstract]: Study aims were to evaluate effects of Bacopa monnieri whole plant standardized dry extract on cognitive function and affect and its safety and tolerability in healthy elderly study participants. The study was a randomized, double-blind, placebo-co

Key Evidence #3
Public scholarly dataCitation signal: 264
review

[Abstract]: This review synthesizes behavioral research with neuromolecular mechanisms putatively involved with the low-toxicity cognitive enhancing action of Bacopa monnieri (BM), a medicinal Ayurvedic herb. BM is traditionally used for various ailments, but

3 more summariesLimited representative sample by study type.
>
Public scholarly dataCitation signal: 183
observational

[Abstract]: The antistress effect of bacosides of Brahmi (Bacopa monnieri, BBM), dissolved in distilled water, was -studied in adult male Sprague Dawley rats by administering oral doses of 20 and 40 mg/kg for 7 consecutive days. In half of the animals treated

Public scholarly dataCitation signal: 152
rct

[Abstract]: The objective of this study was to investigate the effectiveness of Bacopa monnieri Linn. for improvement of memory performance in healthy older persons. This was a randomized, double-blind, placebo-controlled trial. The trial took place in Lismore

Public scholarly dataCitation signal: 135
review

[Abstract]: Bacopa monnieri has a long history in Ayurvedic medicine for neurological and behavioral defects. To assess its efficacy in improving cognitive function. MEDLINE, EMBASE, CINAHL, AMED, Cochrane Central of clinical trial, WHO registry, Thai Medical

Bacopa
arrow_backBack to list